An van Es-Johansson
Directeur/Membre du Conseil chez SAVARA INC.
Fortune : 1 924 $ au 31/05/2024
Postes actifs de An van Es-Johansson
Sociétés | Poste | Début | Fin |
---|---|---|---|
SAVARA INC. | Directeur/Membre du Conseil | 03/12/2019 | - |
Independent Dir/Board Member | 03/12/2019 | - | |
PLUS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2020 | - |
Independent Dir/Board Member | 01/01/2020 | - | |
LUMOS PHARMA, INC. | Directeur/Membre du Conseil | 13/02/2021 | - |
Independent Dir/Board Member | 13/02/2021 | - | |
van Es Consulting AB | Directeur/Membre du Conseil | - | - |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Directeur/Membre du Conseil | - | - |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Directeur/Membre du Conseil | 01/07/2019 | - |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Directeur/Membre du Conseil | 01/02/2021 | - |
Historique de carrière de An van Es-Johansson
Anciens postes connus de An van Es-Johansson
Sociétés | Poste | Début | Fin |
---|---|---|---|
MEDIVIR AB | Directeur/Membre du Conseil | 09/05/2019 | 05/05/2022 |
Independent Dir/Board Member | 09/05/2019 | 05/05/2022 | |
ALZECURE PHARMA AB | Directeur/Membre du Conseil | 01/09/2018 | 03/03/2020 |
Directeur Technique/Scientifique/R&D | 03/03/2020 | 01/03/2021 | |
░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formation de An van Es-Johansson
Erasmus University Rotterdam | Doctorate Degree |
Statistiques
Internationale
Suède | 7 |
Etats-Unis | 6 |
Pays-Bas | 3 |
Opérationnelle
Director/Board Member | 11 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 10 |
Health Services | 3 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 8 |
---|---|
BIOINVENT INTERNATIONAL AB | Health Technology |
MEDIVIR AB | Health Technology |
PLUS THERAPEUTICS, INC. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
IRLAB THERAPEUTICS AB | Health Technology |
SAVARA INC. | Health Technology |
ALZECURE PHARMA AB | Health Technology |
LUMOS PHARMA, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Health Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
van Es Consulting AB |
- Bourse
- Insiders
- An van Es-Johansson
- Expérience